All In Biotech

Drug Trial Radar · NCT05799157

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris

Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

153

Actual

Start

Feb 28, 2023

Primary completion

Feb 25, 2025

Study completion Feb 25, 2025

Sponsor

Lead sponsor
Veradermics, Inc.Industry
Sponsor type
Industry
First posted
Apr 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris

Conditions

  • Verruca Vulgaris
  • Warts
  • Common Wart

Interventions

  • VDMN-21 Patch Low DoseDrug

    Microneedle patch containing 125 mcg of active drug

  • VDMN-21 Patch High DoseDrug

    Microneedle patch containing 250 mcg of active drug

  • Vehicle PatchDrug

    Placebo microneedle patch containing no active drug (i.e., placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment periodTime frame: Baseline up to Day 134

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Site 07

    Fort Smith, Arkansas

  • Site 16

    San Diego, California

  • Site 02

    Plainfield, Indiana

  • Site 13

    Louisville, Kentucky

  • Site 15

    Baton Rouge, Louisiana

  • Site 09

    New Brighton, Minnesota

  • Site 01

    Anderson, South Carolina

  • Site 06

    Greenville, South Carolina

  • Site 11

    Knoxville, Tennessee

  • Site 03

    Arlington, Texas

  • Site 04

    Austin, Texas

  • Site 10

    College Station, Texas

  • Site 12

    Houston, Texas

  • Site 05

    Pflugerville, Texas

  • Site 14

    Norfolk, Virginia

  • Site 08

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.